We are combining science and innovation to get the right treatment to the right patient at the right time for those with cancer, and chronic and rare diseases. This starts with transforming care making it more proactive, integrated and personalised, matching patients with innovative treatment pathways, embracing transformative technologies and collaborating across the healthcare system.
Advances in treating cancer
We are at the forefront of a transformative movement in oncology, aiming to redefine cancer care. Our goal is to discover, develop, and deliver life-changing cancer therapies to transform patient outcomes and increase the chance of cures.
We are actively attacking cancer from multiple angles, such as targeting cancer cells directly and activating the immune system. We are harnessing the power of combinations with the aim of achieving deeper and more durable responses.
We are building expertise and leadership in critical tumour types. Our objective is to identify and treat cancer at earlier stages, where the greatest potential for cures exists.1
We are also embracing cutting-edge technologies, including computational pathology, circulating tumour DNA (ctDNA), digital health, and data science/AI.
Our global presence creates more opportunities to help make cancer treatment more accessible to eligible and suitable patients.
Advances in treating chronic conditions
We aim to transform care for people living with chronic diseases, deliver long-lasting immunity, and prevent disease by focusing on earlier intervention; we hope to protect vital organs, slow or reverse disease progression, and achieve remission for these often degenerative, debilitating, and life-threatening conditions, so many more people can live better, healthier lives.
- We have an ambition to save lives for the millions living with Cardiovascular, Renal and Metabolism (CVRM) diseases. By deepening our understanding of their interconnections and targeting the mechanisms that drive them, we aim to detect, diagnose and treat people earlier and more effectively – to prevent disease progression.
- Our aspiration is to transform Respiratory & Immunology care, moving beyond symptom control to disease modification, remission and, one day, potentially cure. We are committed to transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases, to address the challenges and vast unmet medical needs patients face.
- We are developing and delivering transformative vaccines and antibodies, providing long-lasting immunity to millions of people where the burden of disease is greatest.
Advances in treating rare diseases
There are more than 10,000 rare diseases, more than 90% of which do not have an approved treatment.2,3 People with rare diseases often face unique challenges in getting the healthcare they need.
Our ambition is to bring innovative treatments to more rare disease patients around the world. By building on the work of Alexion and our unmatched commitment to patients, our people are harnessing the rare opportunity to achieve this through the discovery, development and delivery of life-changing therapies.
With a legacy of pioneering science, we are building a robust and diverse rare disease portfolio, spanning multiple modalities and therapeutic areas. Our work is focused on areas of high unmet patient need where we can have the greatest impact on patients’ lives.
Through human ingenuity, amplified by pioneering technology, our goal is to turn science into more effective medicine more quickly than ever before, contributing to better outcomes and individual experiences.
The strength of our science and innovation allows us to be ambitious in our research and development, focusing on where we can have a significant impact on meeting the unmet needs of patients across many diseases. Through collaboration, we can continue to help change the trajectory of care – diagnosing and treating patients earlier and integrating transformative technologies that drive better outcomes for more people, society, and our planet.
Good health is what we all desire for ourselves and our loved ones but achieving something this significant for as many people as possible can’t be accomplished through a single lens, or by acting alone. Science is most powerful when we see health as integral to people, society and our planet. When we continually push forward, progressing our understanding of disease. And when our talented teams are part of like-minded collaborations and partnerships, co-creating innovative solutions that transform care. Together, this is helping to make a big difference to our health.
Topic:
References:
1. Cancer. World Health Organization. Available from: https://www.who.int/health-topics/cancer#tab=tab_3 Accessed October 2024.
2. Fermaglich, L.J., Miller, K.L. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis 18, 163 (2023). https://doi.org/10.1186/s13023-023-02790-7
3. About GARD. U.S. Department of Health and Human Services; [cited 2024 Jan 17]. Available from: https://rarediseases.info.nih.gov/about. Accessed October 2024.
Veeva ID: Z4-69100
Date of preparation: October 2024